CORTICOSTEROIDS AND VASCULAR CONNECTIVE TISSUE

1969 ◽  
Vol 60 (4) ◽  
pp. 586-594 ◽  
Author(s):  
Ib Lorenzen
Keyword(s):  
Body Weight ◽  
Connective Tissue ◽  
Human Skin ◽  
Term Treatment ◽  
Collagen Content ◽  
Acid Mucopolysaccharides ◽  
Long Term Treatment

ABSTRACT Male albino rabbits were injected with prednisone 2 mg/kg body weight, daily for two weeks. The aortic content of acid mucopolysaccharides and the synthesis of sulphated acid mucopolysaccharides decreased, whereas the collagen content remained unchanged as compared to the saline injected controls. Prednisone induced no gross or microscopic changes in the aortae. The alterations were related to those previously reported in human skin and vein biopsies and may be of pathogenic significance in the vascular fragility following long-term treatment with glucocorticoids.

CORTICOSTEROIDS AND VASCULAR CONNECTIVE TISSUE.

1969 ◽  
Vol 62 (1) ◽  
pp. 67-76 ◽  
Author(s):  
Ib Lorenzen
Keyword(s):  
Connective Tissue ◽  
Arterial Wall ◽  
Aortic Wall ◽  
Vascular Wall ◽  
Term Treatment ◽  
Mechanical Trauma ◽  
Repair Processes ◽  
Acid Mucopolysaccharides ◽  
Long Term Treatment

ABSTRACT Male albino rabbits were injected daily with noradrenaline plus prednisone and noradrenaline plus saline for two weeks. Prednisone enhanced the development of the gross and microscopic arteriosclerotic lesions of the aorta induced by noradrenaline, but inhibited the synthesis and the accumulation of acid mucopolysaccharides elicited by the noradrenalineinduced damage of the aortic wall. The effect of prednisone on the aortic acid mucopolysaccharides reflects an inhibition of repair processes in the arterial wall. The enhancement of the arteriosclerosis may be explained by a decrease in the resistance of the aortic wall to mechanical trauma, possibly as a consequence of the effects of prednisone on the arterial mucopolysaccharides demonstrated in the present and the previous study. It is suggested, that the increased liability to skin-haemorrhages in patients given long-term treatment with glucocorticoids is due to an increased vascular fragility conditioned by the glucocorticoid-induced alterations in the mucopolysaccharides of the vascular wall.

scholarly journals Effect of guar gum on body-weight, hunger ratings and metabolism in obese subjects

1984 ◽  
Vol 52 (1) ◽  
pp. 97-105 ◽  
Author(s):  
Marcin Krotkiewski
Keyword(s):  
Body Weight ◽  
Dietary Habits ◽  
Guar Gum ◽  
Term Treatment ◽  
Total Serum ◽  
Glucose Levels ◽  
Cholesterol Levels ◽  
Long Term Treatment ◽  
Obese Subjects

1. The effect of a palatable granulated guar-gum preparation (10 g twice daily) was studied in obese subjects. The acute effect of a single dose of guar gum to reduce the peak postprandial whole blood glucose levels (about 10%) was verified. Following long-term treatment, a further reduction was seen in the obese subjects with the highest postprandial glucose levels. Since the postprandial plasma insulin levels were essentially unchanged, this finding suggested an increased responsiveness to insulin. Total serum cholesterol levels were significantly reduced following long-term treatment but serum α-cholesterol levels, representing the high-density-lipoprotein fraction, was unchanged.2. Body-weight was significantly reduced during guar-gum treatment even though the patients were asked to maintain their normal dietary habits. Daily hunger ratings recorded for up to 10 weeks showed that guar gum reduced hunger significantly better than commercially available bran taken in the same way.3. Thus, guar gum seemed to influence carbohydrate and lipid metabolism in a beneficial way in obese subjects. The reduction in hunger would offer an additional benefit to these patients.

scholarly journals Long term treatment with ACE inhibitor enalapril decreases body weight gain and increases life span in rats

2009 ◽  
Vol 78 (8) ◽  
pp. 951-958 ◽  
Author(s):  
Edson Lucas Santos ◽  
Kely de Picoli Souza ◽  
Elton Dias da Silva ◽  
Elice Carneiro Batista ◽  
Paulo J. Forcina Martins ◽  
...  
Keyword(s):  
Body Weight ◽  
Weight Gain ◽  
Life Span ◽  
Ace Inhibitor ◽  
Body Weight Gain ◽  
Term Treatment ◽  
Long Term Treatment

LONG-TERM TREATMENT WITH ORAL TORSEMIDE AND ITS EFFECT ON BODY WEIGHT AND FLUID BALANCE IN PATIENTS WITH CHRONIC RENAL INSUFFICIENCY

1996 ◽  
Vol 3 (11) ◽  
pp. 743-749
Author(s):  
Andrew Whelton ◽  
William B. Smith ◽  
J. David Wallin ◽  
Lawrence J. Hak ◽  
Barry McLean ◽  
...  
Keyword(s):  
Body Weight ◽  
Renal Insufficiency ◽  
Fluid Balance ◽  
Chronic Renal Insufficiency ◽  
Term Treatment ◽  
Long Term Treatment

1400 EFFECTS OF LONG-TERM TREATMENT WITH TESTOSTERONE UNDECANOATE INJECTIONS IN HYPOGONADAL MEN ON WAIST CIRCUMFERENCE, BODY WEIGHT AND BMI

2013 ◽  
Vol 189 (4S) ◽  
Author(s):  
Dany-Jan Yassin ◽  
Ahmad Haider ◽  
Michael Zitzmann ◽  
Aksam Yassin ◽  
Peter Hammerer ◽  
...  
Keyword(s):  
Body Weight ◽  
Waist Circumference ◽  
Term Treatment ◽  
Testosterone Undecanoate ◽  
Long Term Treatment

scholarly journals 186 Results From a 12-Month Open-label Safety Study of Lumateperone (ITI-007) in Patients with Stable Symptoms of Schizophrenia

CNS Spectrums ◽  
2020 ◽  
Vol 25 (2) ◽  
pp. 317-318
Author(s):  
Christoph U. Correll ◽  
Kimberly E Vanover ◽  
Suresh Durgam ◽  
Robert Davis ◽  
William Rowe ◽  
...  
Keyword(s):  
Body Weight ◽  
Severe Depression ◽  
Term Treatment ◽  
Motor Symptom ◽  
Depression Symptoms ◽  
Open Label ◽  
Antipsychotic Therapy ◽  
Acute Schizophrenia ◽  
Long Term Treatment

Abstract:Introduction:Lumateperone (lumateperone tosylate, ITI-007) is an investigational drug for the treatment of schizophrenia, bipolar depression, and other disorders. Lumateperone has a unique mechanism of action that simultaneously modulates serotonin, dopamine, and glutamate neurotransmission. This may provide advantages in the treatment of the broad symptoms associated with schizophrenia, including negative and depression symptoms. In 2 previous placebo-controlled trials in patients with acute schizophrenia, lumateperone 42mg (ITI-007 60mg) demonstrated statistically significant improvement in the Positive and Negative Syndrome Scale (PANSS) Total score compared with placebo. In these studies, lumateperone was well tolerated with a safety profile similar to placebo. This open-label long-term study evaluated the safety and effectiveness of lumateperone 42mg in patients with schizophrenia and stable symptoms.Methods:Patients with stable schizophrenia were treated for up to 1 year with lumateperone 42mg. Safety assessments included adverse events (AEs), body weight, laboratory parameters, and extrapyramidal symptoms (EPS)/motor symptom assessments. Efficacy analyses included evaluation of changes in PANSS Total score and in depression symptoms, as measured by the Calgary Depression Scale for Schizophrenia (CDSS).Results:In the 1-year open-label study, 602 patients received at least 1 dose of lumateperone 42mg; at the time of this interim analysis, 107 patients had completed 1 year of treatment. Only 4 TEAEs occurred in ≥5% of patients (weight decrease, dry mouth, headache and diarrhea); the majority of AEs were mild or moderate in intensity. Most metabolic parameters and mean prolactin levels decreased from SOC baseline, as did mean body weight and BMI. Based on AE reporting and EPS/motor symptom scales, lumateperone treatment was associated with minimal EPS risk. Lumateperone 42mg treatment was associated with significant reductions in PANSS Total score from baseline, with continuing PANSS improvement throughout the study. In patients with moderate-to-severe depression symptoms at baseline (CDSS>5), mean CDSS scores decreased from 7.4 (baseline) to 3.1 (Day 300); 60% of patients met CDSS response criteria (50% improvement from baseline) by Day 75 and this response rate was maintained through day 300. Similar magnitude of CDSS improvement was seen regardless of concurrent antidepressant therapy.Conclusion:In long-term treatment, lumateperone was associated with minimal metabolic, EPS, and cardiovascular safety issues relative to current SOC antipsychotic therapy. Lumateperone improved schizophrenia symptoms with continued long-term treatment. In patients with moderate-to-severe depression symptoms at baseline, lumateperone treatment was associated with marked improvement in CDSS scores. These data are consistent with and extend data previously reported in placebo-controlled studies in patients with acute schizophrenia treated with lumateperone.Funding Acknowledgements:Supported by funding from Intra-Cellular Therapies, Inc.

Effect of long-term treatment with an anticholinergic drug on parietal cell mass in rats

1969 ◽  
Vol 47 (4) ◽  
pp. 402-405
Author(s):  
K. Kowalewski
Keyword(s):  
Body Weight ◽  
Parietal Cell ◽  
Anticholinergic Drug ◽  
Cell Mass ◽  
Term Treatment ◽  
Parietal Cells ◽  
Long Term Treatment ◽  
Propantheline Bromide

An anticholinergic drug, propantheline bromide, was given to rats in a dosage of 5 mg/kg body weight twice daily, for 6, 9, or 12 months. Parietal cell mass was determined in these animals and in controls of similar age and weight. A significant decrease in the number of parietal cells was found in the stomachs of treated rats. This was considered to represent an "inhibition hypoplasia" produced experimentally.

Sign in / Sign up

Export Citation Format

Share Document